Intralesional Therapy With Anti-CD20 Monoclonal Antibody Rituximab in Primary Cutaneous B-Cell Lymphoma | Zendy

Lucie Heinzerling | Zendy; Reinhard Dummer | Zendy; Werner Kempf | Zendy; M.-H. Schmid | Zendy; G. Burg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intralesional Therapy With Anti-CD20 Monoclonal Antibody Rituximab in Primary Cutaneous B-Cell Lymphoma

Author(s) -

Lucie Heinzerling,

Reinhard Dummer,

Werner Kempf,

M.-H. Schmid,

G. Burg

Publication year - 2000

Publication title -

archives of dermatology

Language(s) - English

Resource type - Journals

eISSN - 1538-3652

pISSN - 0003-987X

DOI - 10.1001/archderm.136.3.374

Subject(s) - medicine , rituximab , lymphoma , cd20 , adverse effect , radiation therapy , scalp , surgery , pathology

We report the use of a new treatment modality in 2 patients with primary cutaneous B-cell lymphoma. In a 58-year-old woman with progressive nodular lesions on the scalp and face, several treatment attempts either failed or could not be used because of severe adverse effects and underlying epilepsy. The patient declined radiotherapy. A 30-year-old man presented with recurrence of tumor nodules occipitally, thoracically, on the arm, and on the right thigh after several excisions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research